Technical Analysis for BRNS - Barinthus Biotherapeutics plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Boomer Sell Setup | Bearish Swing Setup | 9.70% | |
| Calm After Storm | Range Contraction | 9.70% | |
| Lower Bollinger Band Walk | Weakness | 9.70% | |
| Inside Day | Range Contraction | 9.70% | |
| Wide Bands | Range Expansion | 9.70% | |
| Lower Bollinger Band Touch | Weakness | 9.70% | |
| Oversold Stochastic | Weakness | 9.70% | |
| Calm After Storm | Range Contraction | 11.06% | |
| Lower Bollinger Band Walk | Weakness | 11.06% | |
| Inside Day | Range Contraction | 11.06% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 1 hour ago |
| Rose Above Previous Day's High | about 1 hour ago |
| Up 10% | about 1 hour ago |
| Up 5% | about 3 hours ago |
| Up 3% | about 3 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/07/2024
Barinthus Biotherapeutics plc Description
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Immunotherapy Virotherapy Medical Research Carcinogens Papillomavirus HPV Immunotherapeutics Chronic Hbv Infection Human Papillomavirus Infection
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.1591 |
| 52 Week Low | 0.81 |
| Average Volume | 44,079 |
| 200-Day Moving Average | 1.85 |
| 50-Day Moving Average | 1.27 |
| 20-Day Moving Average | 1.32 |
| 10-Day Moving Average | 1.20 |
| Average True Range | 0.14 |
| RSI (14) | 31.03 |
| ADX | 30.71 |
| +DI | 9.57 |
| -DI | 32.85 |
| Chandelier Exit (Long, 3 ATRs) | 1.12 |
| Chandelier Exit (Short, 3 ATRs) | 1.22 |
| Upper Bollinger Bands | 1.75 |
| Lower Bollinger Band | 0.89 |
| Percent B (%b) | 0.01 |
| BandWidth | 65.23 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.0706 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.07 | ||||
| Resistance 3 (R3) | 1.07 | 1.02 | 1.04 | ||
| Resistance 2 (R2) | 1.02 | 0.98 | 1.02 | 1.03 | |
| Resistance 1 (R1) | 0.96 | 0.95 | 0.93 | 0.96 | 1.02 |
| Pivot Point | 0.91 | 0.91 | 0.90 | 0.91 | 0.91 |
| Support 1 (S1) | 0.85 | 0.87 | 0.82 | 0.84 | 0.78 |
| Support 2 (S2) | 0.80 | 0.84 | 0.79 | 0.77 | |
| Support 3 (S3) | 0.73 | 0.80 | 0.76 | ||
| Support 4 (S4) | 0.73 |
